NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE232693 Query DataSets for GSE232693
Status Public on Aug 03, 2023
Title Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_2]
Organism Homo sapiens
Experiment type Expression profiling by array
Summary The majority of BRAFV600 mutant melanomas regress in response to BRAF/MEK inhibitors (BRAFi/MEKi). Yet nearly all relapse within the first two years. Most BRAFi/MEKi-resistant tumors are cross-resistant to immunotherapies, highlighting the need to prevent and circumvent resistance. We recently showed that androgen receptor (AR) activity is required for sustained melanoma cells proliferation and tumorigenesis. Here we find that AR expression is markedly increased in BRAFi resistant melanoma cells as well as in sensitive cells already at very early times of BRAFi exposure. Proliferation and tumorigenicity of BRAFi resistant melanoma cells are blunted by genetic or pharmacologic suppression of AR activity, while AR overexpression is by itself sufficient to rendersmelanoma cells BRAFi/MEKi-resistant. Increased AR elicits transcriptional changes linked with AXL-positive BRAFi resistant subpopulations and induces expression of PAI-1 and EGFR, two determinants of melanoma progression that associate with elevated AR expression in clinical cohorts. Our results point to increased AR signaling as a determinant of melanoma BRAFi resistance, which can be counteracted by AR as well as PAI-1 and EGFR inhibitors.
 
Overall design Five different BRAF resistant (BR) melanoma cell lines were established from the parental (P) cells (A375, M121224, M160915, UACC903 and WM9) by continuous culturing in Dabrafenib for a period of 4 weeks, with weekly multistep increases in concentration from 0.5 to 3uM. Parental (P) and BRAF resistant (BR) melanoma cells were collected for transcriptoomic analysis from confluent 10cm dishes. mRNA was extracted using Direct-Zol RNA MiniPrep kit.
Cell line identifier followed by a indication of BRAF resisitant (BR) or parental (P) conditions.
 
Contributor(s) Samarkina A, Youssef MK, Dotto GP
Citation(s) 37838724
Submission date May 17, 2023
Last update date Oct 26, 2023
Contact name Paola Ostano
Organization name Fondazione Edo ed Elvo Tempia
Street address via Malta 3
City Biella
ZIP/Postal code 13900
Country Italy
 
Platforms (1)
GPL23126 [Clariom_D_Human] Affymetrix Human Clariom D Assay [transcript (gene) version]
Samples (10)
GSM7371866 BRAF resistant A375 melanoma cells
GSM7371867 Parental A375 melanoma cells
GSM7371868 BRAF resistant M121224 melanoma cells
This SubSeries is part of SuperSeries:
GSE232697 Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance
Relations
BioProject PRJNA973594

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE232693_RAW.tar 244.8 Mb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap